Podcast
 |
| On this edition of The Burrill Report: Jim Greenwood, president and CEO of the Biotechnology Industry Organization, discusses the uncertainty surrounding healthcare reform, what it means for issues such as follow-on biologics, and what the industry's policy agenda looks like for 2010. |
G. Steven Burrill
Welcome from the CEO
Flash required to view this video. Download the latest version here
G. Steven BurrillNews
Biotech holds steady in January as broader markets head south February 01, 2010 | Press Release
Biotech Closes the Year on an Upswing January 04, 2010 | Press Release
Biotech gets back on track in November December 01, 2009 | Press Release
See all News
Burrill Media is the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publishes a wide range of bio-intelligence reports. Annual conferences include The Biotech Meeting, The Indiana Life Sciences Forum, The Burrill Personalized Medicine Meeting, The Aging Meeting and The Stem Cell Meeting. Burrill Media publications include the annual State of the Industry, The Personalized Medicine Report, The Stem Cell Report, and periodic newsletters covering Canada, China, Europe, India, Japan and Partnering/M&A. Burrill also publishes The Burrill Report, a monthly digital publication.
Biotech 2009-Life Sciences: Navigating the Sea Change (electronic) (AZBIO)
Sea change: Noun: a striking change, as in appearance, often for the better
Biotech 2009-Life Sciences: Navigating the Sea Change is the 23rd edition of this yearly publication. It provides a compass to guide you through the current financial market turmoil. The 400-plus page book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond.
Biotech 2009-Life Sciences: Navigating the Sea Change is the 23rd edition of this yearly publication. It provides a compass to guide you through the current financial market turmoil. The 400-plus page book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond.
The biotech industry has had nearly 40 years of easy access to inexpensive capital. The capital markets have permanently restructured, making access to capital more difficult and expensive to access. The changes mean:
§ Buy-side interest and resources are reduced.
§ Venture capitalist and private investors no longer can rely on IPOs for exits.
§ Big Pharma is not as eager to make deals. As these companies see it, technology will be cheaper to buy if they wait.
§ Falling oil prices may slow the momentum for alternate fuels.
Click here to view the table of contents.
NOTE: This is a single user license. This product is not for copying, redistribution, or posting on a corporate server. For a multi-user license, please contact Peter Winter at pwinter@b-c.com or 415-591-5474.
Add to cart$395.00